CompuGROUP and Knappschaft Bahn See Launch Pilot Programme

CompuGROUP Holding AGCompuGROUP Holding AG, the e-health service company with the broadest reach among service providers world-wide, is now supporting the integrated treatment of patients suffering from Type 2 diabetes mellitus through its subsidiary GIV. Client Knappschaft Bahn See expects the programme to provide more effective patient care and reduce costs significantly.

In the fourth quarter of 2008, Knappschaft Bahn See and the CompuGROUP subsidiary Gesellschaft für angewandte integrierte Versorgungsformen (GiV) mbH in the Saarland launched an innovative, fully practicable, integrated treatment programme: prosper Versorgungsmanagement Diabetes. The goal is to optimize treatment in order to improve the health of manifest diabetics and risk patients on a sustained basis. Apart from this top-priority medical goal, the programme is also expected to reduce the consequential costs of diabetes, which account for up to 80% of total treatment costs for these patients.

The foundation of the prosper programme is a health-care network established by Knappschaft and composed of family doctors, specialists and hospitals in a given region. The prosper Saar health-care network consists of over 300 physicians, of whom 50 are now participating in the interdisciplinary, cross-sector prosper Versorgungsmanagement Diabetes programme.

The heart of prosper Versorgungsmanagement Diabetes consists of a central, indication-based case file and an innovative diagnostic and treatment path derived from data contained in the file - both elements developed by CompuGROUP. All relevant information is entered in the file by participating physicians. It includes comprehensive treatment data on Type 2 diabetes patients as well as information about identified risk patients. On the basis of this medical data, the treatment path provides specific guideline-oriented recommendations for treatment teams at the moment a medical decision needs to be made. The diabetes mellitus path was developed by the medical team at CompuGROUP in consultation with the renowned expert Prof. Dr. Werner Scherbaum of Düsseldorf. "Our goal is to offer doctors only those 'bits of information' they really need - at precisely the right moment and integrated directly into the physician's workflow", explains Frank Ladendorf, Managing Director of GiV.

Prof. Dr. med. Werner Scherbaum, Director of the Endocrinology, Diabetology and Rheumatology Clinic at the Düsseldorf University Hospital, goes one step further: "The prosper Versorgungsmanagement Diabetes programme responds to the repeatedly expressed appeal for a practicable diagnostic and treatment system controlled primarily by family physicians. Specialist treatment can be integrated without difficulty. Making the best use of existing resources, developing them through innovation and thus doing more for patients and their health - these are the primary objectives of prosper Versorgungsmanagement Diabetes."

Frank Ladendorf emphasizes the potential savings for health insurers: "We are already seeing evidence that prosper Versorgungsmanagement Diabetes enhances the efficiency of patient treatment while ensuring quality and cost-effectiveness on a sustainable basis. Our software makes a valuable contribution in that context. I'm sure", Ladendorf adds, "that other health insurers will soon be using intelligent-software-aided systems of this kind to increase efficiency as well."

"We hope to find out", says Hans Adolf Müller, Health Management Director at Knappschaft Bahn See, "whether this innovative decision-support system will enable us to help our policyholders more effectively and to provide more systematic support to treating physicians and their teams." CompuGROUP has proven to be a strong partner. As the market leader, CompuGROUP has broad, central access to practising physicians thanks to the widespread use of its physicians' information system.

According to Frank Ladendorf, "Treatment management systems of this kind work only if they are accepted by physicians. We gain that acceptance by integrating the system into existing workflows and by ensuring complete transparency - with respect to prescriptions, for example." The pilot project is scheduled to run until the end of 2009, after which it will be evaluated for the purpose of assessing the practicability and the added benefits of this form of integrated treatment. If the positive results shown thus far are confirmed, the programme will be launched on a broad basis and expanded to include other guideline-oriented patient paths for other widespread diseases in 2010.

Related news articles:

About CompuGROUP Holding AG
CompuGROUP is one of the leading e-health companies worldwide. Its software products, designed to support all medical and organizational activities in doctors' offices and hospitals, its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. The services of CompuGROUP are based on its unique customer base of around 326,000 doctors, dentists, hospitals and networks as well as other service providers. CompuGROUP is the e-health company with the biggest coverage among e-health service providers worldwide. The company operates in 14 European countries, Malaysia, Saudi Arabia, South Africa and in the USA and currently employs around 2,700 people.

Most Popular Now

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

To be Happier, Take a Vacation... from Y…

Today, nearly every American - 91% - owns a cellphone that can access the internet, according to the Pew Research Center. In 2011, only about one-third did. Another study finds...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

Researchers Find Telemedicine may Help R…

Low-value care - medical tests and procedures that provide little to no benefit to patients - contributes to excess medical spending and both direct and cascading harms to patients. A...

AI Revolutionizes Glaucoma Care

Imagine walking into a supermarket, train station, or shopping mall and having your eyes screened for glaucoma within seconds - no appointment needed. With the AI-based Glaucoma Screening (AI-GS) network...

North Cumbria Integrated Care Signs 10-Y…

North Cumbria Integrated Care NHS Foundation Trust (NCIC) has signed a long-term agreement for use of the Alcidion Miya Precision platform, to provide an electronic patient record (EPR) for the...

AI Accelerates Discovery of Neurodevelop…

Researchers have developed an artificial intelligence (AI) approach that accelerates the identification of genes that contribute to neurodevelopmental conditions such as autism spectrum disorder, epilepsy and developmental delay. This new...